Items tagged with Drug-susceptible TB

Update of the WHO guidance on the treatment of drug susceptible TB (post)

The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the treatment of drug susceptible tuberculosis (TB).

WHO announces updates on the treatment of drug-susceptible TB (post)

14 June 2021, Geneva | A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme announced updates to the current treatment regimen for people with TB. A review of evidence by WHO has shown similar performance of a shorter treatment regimen compared to the current standard regimen, both in terms of efficacy and safety. The 4-month regimen, which is shorter, effective and all-oral, would be a preference for many patients and also national TB programmes, allowing faster cure and easing the burden on both patients and the healthcare system. Shortened treatment has the potential to improve adherence and reduce patient and health system costs.

Otsuka awarded grant for Phase 2 trial combining novel anti-tuberculosis compound OPC-167832 with delamanid and bedaquiline (post)

-- Grant up to $17.8 million will support study of treatment-shortening regimen in drug-sensitive tuberculosis (DS-TB)
-- Study expected to begin in 2022 evaluating safety and efficacy of novel 3-drug combination versus existing 4-drug standard of care

ACTG announces initiation of CLO-FAST, its first trial evaluating a three-month TB treatment (post)

10 November 2021: The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB). This is the first TB regimen based on preclinical evidence of effectiveness that is less than four-months long to be studied in a clinical trial. A5362 will evaluate the potential efficacy of clofazimine when combined with treatments that have been proven to be effective against TB.

Point-of-care diagnostics for tuberculosis elimination? (post with simple image)

The projected epidemiological effect of Xpert MTB/RIF might be overestimated, so this fascinating and promising new tool is unlikely to be the magic bullet that paves the way towards tuberculosis elimination.

New tuberculosis drug regimen will move to landmark Phase 3 clinical trial (post with simple image)

STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB.

The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities (post with simple image)

Community voices on bedaquiline's use to treat drug-resistant tuberculosis and future development as a potential treatment for drug-susceptible disease have been largely unheard.

Attempt to shorten standard tuberculosis treatment fails in REMoxTB trial (post with simple image)

Two 4-month treatment regimens containing moxifloxacin are less effective than the standard 6-month regimen for drug-sensitive tuberculosis.

Global Phase 3 “STAND” trial launched to test new tuberculosis drug regimen PaMZ to shorten, improve treatment (post with simple image)

STAND trial will take place in approximately 50 study sites in Africa, Asia, Caribbean, Eastern Europe, and Latin America; Results published in The Lancet show PaMZ’s promise to dramatically shorten and simplify therapy for patients with drug-resistant TB; Regimen could improve treatment for those with drug-sensitive TB and those with HIV co-infection.

Page 2 of 3 · Total posts: 0

←First 1 2 3 Last→